{"id":"NCT03305016","sponsor":"Ascendis Pharma Endocrinology Division A/S","briefTitle":"A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency","officialTitle":"fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-11-13","primaryCompletion":"2019-03-19","completion":"2019-03-19","firstPosted":"2017-10-09","resultsPosted":"2022-01-04","lastUpdate":"2022-01-04"},"enrollment":146,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Growth Hormone Deficiency, Pediatric","Endocrine System Diseases","Hormone Deficiency","Pituitary Diseases"],"interventions":[{"type":"DRUG","name":"TransCon hGH","otherNames":[]}],"arms":[{"label":"TransCon hGH","type":"EXPERIMENTAL"}],"summary":"A 26 week trial of TransCon hGH, a long-acting growth hormone product, administered once-a-week. Approximately 150 children (males and females) with growth hormone deficiency (GHD) will be included. All study participants will receive TransCon hGH. This is a global trial that will be conducted in, but not limited to, the United States, Canada, Australia, and New Zealand.","primaryOutcome":{"measure":"Number of Participants With Treatment-Emergent Adverse Events [Safety and Tolerability]","timeFrame":"26 weeks","effectByArm":[{"arm":"Lonapegsomatropin","deltaMin":83,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":24,"countries":["United States","Australia","Canada","New Zealand"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":146},"commonTop":["Pyrexia","Nasopharyngitis","Upper respiratory tract infection","Headache","Oropharyngeal pain"]}}